Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Oklahoma Healthcare Wire.
Press releases published on June 2, 2025
Cronos Group Inc. to Speak at the TD Cowen 9th Annual Future of the Consumer Conference
GlobeNewswire
·
June 2, 2025
TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President and CEO, will speak at the TD Cowen 9th …
Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates
GlobeNewswire
·
June 2, 2025
BOSTON and SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for …
Introducing Changent: A Bold New Identity for a National Organization Transforming the Futures of Children and Families
GlobeNewswire
·
June 2, 2025
DENVER, COLO., June 02, 2025 (GLOBE NEWSWIRE) -- The National Service Office (NSO) for Nurse-Family Partnership ® and Child First is thrilled to unveil its new name and brand: Changent. This bold new identity reflects our commitment to strengthening …
‘Stealthy’ Endocrine Effects of the COVID Vaccine Discussed in the Journal of American Physicians and Surgeons
GlobeNewswire
·
June 2, 2025
TUCSON, Ariz., June 02, 2025 (GLOBE NEWSWIRE) -- Endocrine effects that may result from vaccination are deceptively subtle at their onset. Hence, robust and sensitive pharmacovigilance is needed to discover them, writes Jane Orient, M.D., in the summer …
Elite Clinical Network Appoints Christopher Brennan as Chief Executive Officer
GlobeNewswire
·
June 2, 2025
SCOTTSDALE, Ariz., June 02, 2025 (GLOBE NEWSWIRE) -- Elite Clinical Network (ECN), a fully-integrated clinical research site network, has appointed Christopher (“Chris”) Brennan as its Chief Executive Officer. With 25 years of leadership experience at …
Niemann-Pick Disease Market Insights: Key Trends and Developments Across Different Types of Niemann-Pick Disease | DelveInsight
GlobeNewswire
·
June 2, 2025
New York, USA, June 02, 2025 (GLOBE NEWSWIRE) -- Niemann-Pick Disease Market Insights: Key Trends and Developments Across Different Types of Niemann-Pick Disease | DelveInsight According to DelveInsight’s analysis, the market for Niemann-Pick disease is …
PathMaker Neurosystems Announces Rhode Island Life Sciences Hub (RILSH) Funding to Establish Operations in Rhode Island
GlobeNewswire
·
June 2, 2025
BOSTON, MA and PROVIDENCE, RI, June 02, 2025 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (“PathMaker”), a clinical-stage neurotechnology company developing a breakthrough non-invasive approach for treating Amyotrophic Lateral Sclerosis (ALS), today …
OSE Immunotherapeutics Provides Clinical Updates on Neo-Epitope Based Cancer Vaccine Tedopi® in Pancreatic Cancer and Non-Small Cell Lung Cancer
GlobeNewswire
·
June 2, 2025
OSE Immunotherapeutics Provides Clinical Updates on Neo-Epitope Based Cancer Vaccine Tedopi® in Pancreatic Cancer and Non-Small Cell Lung Cancer Two presentations at the American Society of Clinical Oncology (ASCO) 2025: TEDOPaM - Phase 2 first positive …
WellSpan Health and local libraries launch the annual Get Outdoors (GO!) interactive hiking and reading program in central Pennsylvania, expands into new county
GlobeNewswire
·
June 2, 2025
York, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- For the 18th consecutive summer, WellSpan and local libraries across central Pennsylvania are launching an interactive, outdoor scavenger hunt designed to exercise the body and mind known as the Get Outdoors, or …
HOOPP appoints Reena Carter as new Chief Financial Officer
GlobeNewswire
·
June 2, 2025
TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- The Healthcare of Ontario Pension Plan (HOOPP) is pleased to announce the appointment of Reena Carter as Chief Financial Officer (CFO). “Reena has consistently demonstrated strong leadership and financial acumen, …
4D Path Presents Breakthrough Research Demonstrating That Its Unique Digital Predictive Biomarker Identifies Treatment Responders in a Difficult-To-Treat Breast Cancer Patient Population
GlobeNewswire
·
June 2, 2025
NEWTON, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- 4D Path, a company dedicated to personalizing cancer care through its unprecedented approach to predicting tumor response, unveiled groundbreaking findings at the American Society of Clinical Oncology (ASCO …
How to Start Downsizing Your Home: Ginny Fey of Real Estate One Shares Insights in HelloNation Magazine
GlobeNewswire
·
June 2, 2025
TRAVERSE CITY, MI, June 02, 2025 (GLOBE NEWSWIRE) -- The process of downsizing can often feel emotionally and physically overwhelming for older adults facing a home full of memories. Ginny Fey of Real Estate One in Traverse City, Michigan, offers a …
Access Barriers Hamper Early Line Adoption of UCB’s Bimzelx at Six Months Post-Launch in Psoriatic Arthritis and Axial Spondyloarthritis, According to Spherix Global Insights
GlobeNewswire
·
June 2, 2025
EXTON, PA, June 02, 2025 (GLOBE NEWSWIRE) -- Just over six months into its dual launch across Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (axSpA), UCB’s Bimzelx (bimekizumab) is demonstrating meaningful promise, though prescriber momentum remains …
Precede Biosciences Presents ASCO 2025 Data Highlighting the Ability of its Liquid Biopsy Platform to Reveal the Biology Underlying Response and Resistance to ADCs and Radiopharmaceuticals
GlobeNewswire
·
June 2, 2025
Using just 1mL of plasma, the Precede Bio platform identified key molecular pathways linked to response and resistance in patients with metastatic breast and prostate cancer treated with sacituzumab govitecan and 177Lu-PSMA-617, respectively BOSTON, June …
MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients
GlobeNewswire
·
June 2, 2025
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced it has been awarded a …
The Journal of Clinical Oncology Publishes Five-year Analysis of Amtagvi® (lifileucel) in Patients with Advanced Melanoma
GlobeNewswire
·
June 2, 2025
One-time Amtagvi Treatment Continues to Show Deep, Durable Responses and Meaningful Survival One Third of Responses Remain Ongoing without Subsequent Treatment after Five Years Simultaneous Presentation at ASCO 2025 SAN CARLOS, Calif., June 02, 2025 ( …
Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY
GlobeNewswire
·
June 2, 2025
REYKJAVIK, Iceland, June 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies …
Solera Health Unveils Enhanced AI Governance Framework for Responsible and Transparent Use of Artificial Intelligence in Digital Health
GlobeNewswire
·
June 2, 2025
PHOENIX, June 02, 2025 (GLOBE NEWSWIRE) -- Solera Health, the premier digital health delivery company creating flexible solutions to seamlessly connect people to on-benefit care via health plans and employers, today announced the launch of its Enhanced AI …
Full Dose-Escalation Data Show Continued High Response Rates and Favorable Safety Profile of ISB 2001, a First-in-Class BCMA × CD38 × CD3 Trispecific Antibody, for the Treatment of Relapsed/Refractory Multiple Myeloma
GlobeNewswire
·
June 2, 2025
TRIgnite-1 study shows an overall response rate (ORR) of 74% across nine dose levels, in heavily pretreated patients with a median of six prior lines of therapy ORR is remarkably high in patients with no prior CAR-T or bispecific therapies (84%) as well as …
Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types
GlobeNewswire
·
June 2, 2025
SALT LAKE CITY, June 02, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced new molecular residual disease (MRD) clinical data from the MONSTAR-SCREEN 3 study, a …